摘要
心血管疾病是妇女死亡的常见原因之一。关于绝经前和绝经后妇女的具体个性化治疗对心血管危险因素的分析尚未达成共识。在动物和人类研究中观察到临床显着的心脏保护和抗重塑效应,探索慢性抑制5型磷酸二酯酶(PDE5)。 心脏,雌激素和PDE5抑制剂(PDE5is)之间的关系仍不清楚。实验数据表明对女性的心脏几何,功能,内皮功能和微血管冠状动脉血流的潜在有益作用。最近推测,PDE5is的功效是女性心脏病中的雌激素依赖性。目前正在招募患者,登记的随机,安慰剂对照研究,旨在鉴定长期PDE5抑制在糖尿病性心肌病中的性别特异性功效的RECOGITO(NCT01803828)。雌激素受体调节可能是通过PDE5is进行心脏保护的新的有希望的方法。 PDE5可被称为调节心脏功能障碍和重塑中的性别导向策略以及所选心血管疾病的心脏危险因素。
关键词: 性别,雌激素,PDE5is,NO,cGMP,心脏,心血管疾病,内皮功能。
Current Medicinal Chemistry
Title:The Woman’s Heart: Insights into New Potential Targeted Therapy
Volume: 24 Issue: 24
关键词: 性别,雌激素,PDE5is,NO,cGMP,心脏,心血管疾病,内皮功能。
摘要: Cardiovascular disease is an increasingly common cause of death in women. There is as yet no consensus on the analysis of cardiovascular risk factors with regard to the specific, personalised treatment of pre- and post-menopausal women. Clinically significant cardioprotective and antiremodelling effects have been observed in animal and human studies exploring chronic inhibition of phosphodiesterase type 5 (PDE5).
The relationship between the heart, estrogens and PDE5 inhibitors (PDE5is) remains unclear. Experimental data suggest potential beneficial effects on cardiac geometry, function, endothelial function and microvascular coronary flow in women. It was recently postulated that the efficacy of PDE5is is estrogen-dependent in female heart disease. A registered randomised, placebo-controlled study, RECOGITO (NCT01803828), aimed at identifying the genderspecific efficacy of long-term PDE5 inhibition in diabetic cardiomyopathy, is currently recruiting patients. Estrogen receptor modulation could be a new promising approach to heart protection via PDE5is. PDE5is could be indicated as a gender-oriented strategy in modulated cardiac dysfunction and remodelling and in cardiac risk factors for selected cardiovascular diseases.Export Options
About this article
Cite this article as:
The Woman’s Heart: Insights into New Potential Targeted Therapy, Current Medicinal Chemistry 2017; 24 (24) . https://dx.doi.org/10.2174/0929867324666161118121647
DOI https://dx.doi.org/10.2174/0929867324666161118121647 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biomarkers in Lone Atrial Fibrillation-An Additional ‘Fine Tuning’ of Risk?
Current Pharmaceutical Design Sympathetic Nervous System in Patients with Sleep Related Breathing Disorders
Current Hypertension Reviews The Role of Nitro (NO<sub>2</sub>-), Chloro (Cl), and Fluoro (F) Substitution in the Design of Antileishmanial and Antichagasic Compounds
Current Drug Targets Small Transthyretin (TTR) Ligands as Possible Therapeutic Agents in TTR Amyloidoses
Current Drug Targets - CNS & Neurological Disorders The Unaddressed Issue of Optimal Antithrombotic Treatment after Coronary Artery Stenting in Patients with an Indication for Anticoagulation: Current Evidence and Suggested Practice
Vascular Disease Prevention (Discontinued) Angiotensin Type 1 Receptor Blockers in Heart Failure
Current Drug Targets Antithrombotic Treatment after Atrial Fibrillation Ablation
Current Pharmaceutical Design The Potential of Secondary Metabolites from Plants as Drugs or Leads Against Protozoan Neglected Diseases – Part I
Current Medicinal Chemistry Stage A: Can Heart Failure Be Prevented?
Current Cardiology Reviews Renal and Cardiac Effects of Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation
Current Vascular Pharmacology MicroRNAs in the Management of Heart Failure
Current Medicinal Chemistry Genetics of Hypertrophic and Dilated Cardiomyopathy
Current Pharmaceutical Biotechnology Angiotensin-Converting Enzyme Inhibitors: Mechanisms of Action and Implications In Anesthesia Practice
Current Pharmaceutical Design Alteration of the Beta-Adrenergic Signaling Pathway in Human Heart Failure
Current Pharmaceutical Biotechnology Tetracyclic Triterpenoids in Herbal Medicines and their Activities in Diabetes and its Complications
Current Topics in Medicinal Chemistry New Genetic Polymorphisms as an Epidemiological Factor of Arterial Hypertension in Patients with Hyposodical Diet
Current Hypertension Reviews Remodeling of the Myocardium and Potential Targets in the Collagen Degradation and Synthesis Pathways
Current Drug Targets - Cardiovascular & Hematological Disorders The Role of Statins in the Activation of Heme Oxygenase-1 in Cardiovascular Diseases
Current Drug Targets Patent Annotations
Recent Patents on Cardiovascular Drug Discovery The Multi-modality Cardiac Imaging Approach to Cardiac Sarcoidosis
Current Medical Imaging